S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
Log in

LON:AZN - AstraZeneca Share Price, Forecast & News

GBX 7,102
-114.00 (-1.58 %)
(As of 04/1/2020 02:01 PM ET)
Add
Compare
Today's Range
6,918
Now: GBX 7,102▼
7,127
50-Day Range
6,221
MA: GBX 7,106.56▼
7,710
52-Week Range
5,626
Now: GBX 7,102▼
8,227.88
Volume2.87 million shs
Average Volume2.31 million shs
Market Capitalization£93.19 billion
P/E Ratio69.22
Dividend Yield3.17%
BetaN/A
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More
AstraZeneca logo

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolLON:AZN
Previous Symbol
CUSIPN/A
CIKN/A
Webhttp://www.astrazeneca.com/
Phone+44-20-73045000

Debt

Debt-to-Equity Ratio139.95
Current Ratio0.86
Quick Ratio0.63

Price-To-Earnings

Trailing P/E Ratio69.22
Forward P/E Ratio18.59
P/E GrowthN/A

Sales & Book Value

Annual Sales£24.38 billion
Price / Sales3.82
Cash FlowGBX 483.57 per share
Price / Cash Flow14.69
Book ValueGBX 1,000.40 per share
Price / Book7.10

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees64,400
Outstanding Shares1,312,189,952
Market Cap£93.19 billion
Next Earnings Date4/29/2020 (Estimated)
OptionableOptionable

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

LSE:AZN Rates by TradingView

AstraZeneca (LON:AZN) Frequently Asked Questions

How has AstraZeneca's stock been impacted by COVID-19 (Coronavirus)?

AstraZeneca's stock was trading at GBX 6,955 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AZN stock has increased by 2.1% and is now trading at GBX 7,102. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AstraZeneca.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Wednesday, April 29th 2020. View our earnings forecast for AstraZeneca.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Friday, February 14th. Investors of record on Thursday, February 27th will be paid a dividend of GBX 146.40 per share on Monday, March 30th. This represents a dividend yield of 1.92%. The ex-dividend date of this dividend is Thursday, February 27th. This is a positive change from AstraZeneca's previous dividend of $71.90. The official announcement can be seen at this link. View AstraZeneca's dividend history.

What price target have analysts set for AZN?

18 analysts have issued 12 month price targets for AstraZeneca's stock. Their forecasts range from GBX 6,000 to £100. On average, they anticipate AstraZeneca's stock price to reach GBX 7,829.38 in the next year. This suggests a possible upside of 10.2% from the stock's current price. View analysts' price targets for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

News headlines about AZN stock have trended very positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAstraZeneca.

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Vodafone Group (VOD), Hain Celestial Group (HAIN), NVIDIA (NVDA), National Retail Properties (NNN), BP (BP), Royal Dutch Shell (RDSB), Marks and Spencer Group (MKS), Encana (ECA) and Philip Morris International (PM).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately GBX 7,102.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of £93.19 billion and generates £24.38 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe. View additional information about AstraZeneca.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com/.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.


MarketBeat Community Rating for AstraZeneca (LON AZN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  1,553 (Vote Outperform)
Underperform Votes:  1,735 (Vote Underperform)
Total Votes:  3,288
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: What are popular green investing opportunities?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel